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Abstract
Background: Apoptosis is an important mechanism that is responsible for the physiological deletion of harmful, 
damaged, or unwanted cells. Changed expression of apoptosis-related genes may lead to abnormal cell prolifera-
tion and finally to tumorigenesis. Our aims were to analyze the promoter methylation and gene expression profiles 
of FADD and FAS genes in risk of OSCC.
Material and Methods: we analyze the promoter methylation status of FADD and FAS genes using Methylation - 
Specific PCR (MSP) in 86 OSCC tissues were kept in paraffin and 68 normal oral tissues applied as control. Also, 
FADD and FAS genes expression were analyzed in 19 cases and 20 normal specimens by Real-Time Reverse-
Transcripts PCR.
Results: Aberrant promoter methylation of FADD and FAS genes were detected in 12.79 % (11 of 86) and 60.46 
% (52 of 86) of the OSCC cases, respectively, with a significant difference between cases and healthy controls 
for both FADD and FAS genes (P<0.001). The gene expression analysis showed statistically significant difference 
between cases and healthy controls for both FADD (p<0.02) and FAS (p<0.007) genes.
Conclusions: To the best our knowledge, the data of this study are the first report regarding, the effect of promoter 
hypermethylation of the FADD and FAS genes in development of OSCC. To confirm the data, it is recommended 
doing further study in large sample sizes in various genetic populations.                                                                                           
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Introduction
Head and neck cancer holds the sixth place in the can-
cer incidence ranking worldwide, influencing almost 
650,000 people and causing nearly 350,000 cancer 
deaths each year  (1,2). Among all of the head and neck 
cancers, Oral Squamous Cell Carcinoma (OSCC) is the 
most prevalent malignant epithelial neoplasm influenc-
ing the oral cavity (3).
The incidence and development of OSCC are multi 
stage processes, which arises through a collection of 
genetic and epigenetic variations (4). DNA methylation, 
as a key epigenetic variation is necessary for normal 
differentiation and development. The aberrant DNA 
promoter methylation that influences gene expression 
is a common feature of many human cancers (5). With 
respect to OSCC development, recent works demon-
strated that hypermethylation of CpG islands of genes 
that are implicated in apoptosis, DNA-repair, cell-cell 
adhesion, and cell cycle regulation plays a vital role in 
cancer progression (6-9).
Apoptosis or programmed cell death deals with a sig-
nificant task in the maintenance of cellular homeosta-
sis. The inactivation of apoptosis related genes may lead 
to unusual cell proliferation and tumorgenesis (10-11). 
Generally, apoptosis is regulated by two major path-
ways: the receptor-mediated and the intrinsic (mitochon-
drial) pathways (12). Fas (CD95/Apo1) are a cell surface 
receptor that belongs to tumor necrosis factor receptor 
(TNF-R) family. Physiologically, it is expressed in vari-
ous tissues such as lymph nodes, spleen and on mature 
hematologic cells (13-14). 
Fas Ligand (FasL) is a homotrimeric protein act as a ligand 
for Fas receptor and causes its oligomerization. This pro-
cess vast through the death domain (DD) and Fas-associat-
ed death domain (FADD). The N-terminal region of FADD 
which comprises DED (Death Effector Domain) motif 
binds to a homologous motif in Procaspase-8. Caspase-8 
activates caspase-3 and -7 that mediate cell death. Fur-
thermore, it cleaves Bid to generate truncated Bid (tBid) 
which translocates to the mitochondria and triggers the 
mitochondrial apoptotic pathway (15,16). Aberrant pro-
moter methylation of FAS and FADD gene were exposed 
in different types of human cancers (17). Further, Fas is 
expressed in high quantities in lower stage of OSCC and a 
high incidence of FADD expression was significantly cor-
related with lymph node metastasis of SCCs (18,19). The 
data have been reported rarely, regarding to the status of 
the methylation and expression profile of FADD and FAS 
genes in OSCC tissues. Hence, the present study is try-
ing to highlight the expression and methylation profile of 
FADD and FAS genes in patients with OSCC.
Material and Methods
-Samples and DNA preparation
This study involves 86 tumor specimens of OSCC (mean 
age 54.37 ±14) that had been fixed in Paraffin and 68 oral 
mucosa biopsies as controls (mean age 41±14) were col-
lected during surgical resections of oral region squamous 
cell of patient’s (gingival aria) with-out a history of OSCC 
who were referred to Periodontics Department, after ex-
planation of study purpose and signing of consent form. 
Clinic pathological data of the patients and the controls 
such as age, sex, and clinical stage are shown in table 
1 and 2. Genomic DNA was isolated from tumor and 
healthy tissue samples using QIAamp DNA extraction 
kit (Cat. No. 56404, Qiagen) according to the manufac-
Characteristics Cases 
n=86
Methylation status a
M              U
P value Controls
n=68
Methylation status
M                U
P value
Age (years)
<50
>50
27
59
17
36
10
23
0.5 49
19
14
8
35
11
0.5
Sex
Male
Female
41
45
26
27
15
18
0.1
0.02
27
41
11
11
16
30
0.5
Stage
I
II
Well differentiated
Moderately
Metastatic
19
17
37
8
5
14
10
19
6
4
5
7
18
2
1
0.6
-
-
-
-
-
Table 1. Association between Fas gene promoter methylation and clinicocopathological parameters in patients with OSCC and health controls.
a M methylated, U unmethylated  
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turer’s instructions and then its quality was estimated 
by Spectrophotometer.
-Methylation-Specific PCR (MSP)
The process of bisulfit modification of DNA samples 
was performed as previously described (20). Methyla-
tion status of the promoter regions of FADD and FAS 
was determined by Methylation-Specific PCR (MSP) 
using methylated specific and unmethylated specific 
primers was designed at CpG sites of the promoter re-
gion using MatPrime online software (Fig. 1, Table 3).
The PCR reaction mixture included 2 μL of modified tem-
plate DNA, 0.2 µL of HotStarTaq®, 1 µL of dNTP mix (10 
µmol/L), 16.3 µL of RNase free double distilled water, 2.5 
µL of 10× buffer, 0.5 µL of each primer (10 µmol/L), and 2 
µL of Mg2+ (25 µmol/L) in total (a) volume of 25 µL.
MSP amplification was performed as follows: 94°C for 
10 min; and then 40 cycles consisting of (40 s at 94°C, 
30 s at 51°C for FADD (M), 54°C (U), and for FAS 60°C 
(M), 62°C (U), 1 min at 72), and a final extension at 72°C 
for 10 min. PCR products were loaded onto 4% agarose 
gel and stained with ethidium bromide (Figs. 2,3).
-Gene expression analysis
Total RNA was extracted from OSCC fixed paraffin 
embedded tissue sections and fresh normal samples 
that had been taken during various surgical operations 
in oral region, except of cancerous cases. It were used 
(Using) the High Pure FFPE RNA Micro Kit) Cat No: 
04823125001 (and Cinna Pure RNA Purification Kit) 
Cat No: PR891620 (respectively, according to the manu-
facturer’s instructions.
The cDNA Synthesis Kit (Fermentas, Cat No: K1621) 
was used to reverse-transcribe 1 μg of RNA in a final 
volume of 20 μl. As an internal standard, RNA18S was 
used. Real time-PCR of Fadd and Fas were performed 
using the primers and annealing temperatures in table 
Characteristic C a s e s 
N=86
Methylation status
M               U
P value Controls N=68
Methylation status
M                U
Age (years)
<50
>50 2759
4
7
23
52
0.009 49
19
0
0
49
19
Sex
Male
Female 4145
7
4
34
41
0.023
0.05
27
41
0
0
27
41
Stages
I
II
Well differentiated
moderately
metastatic
19
17
37
8
5
4
1
4
1
1
15
16
33
7
4
0.7
-
--
-
-
-
Table 2. Association between FADD gene promoter methylation and clinicocopathological parameters in patients with OSCC 
and health controls
4. Cycle threshold (CT) at which the fluorescence for 
the reaction well crosses was recognized for each gene 
in all samples and then, normalized CT (CT target gene/
CT housekeeping gene) was used for comparison of 
genes expression between groups.
-Statistical analysis
Data were analyzed using SPSS software. The chi-
square test was used for categorical variables. The ef-
fect of the methylation of FADD and FAS genes on the 
risk of OSCC was detected by estimating odds ratios 
(OR) and 95% confidence intervals (95% CI) using the 
binary logistic regression test. Analysis of relative gene 
expression between patients and controls was done by 
mann-whitney test. The significance level was set at 
p≤0.05 for all the tests.
Results
-Promoter methylation of FADD and FAS 
Promoter methylation status of the FADD and FAS genes 
in patients and healthy individuals and their relationship 
with risk of OSCC is indicated in tables 5 and 6. As 
shown, the frequency of methylation status for FADD 
gene was 12.79 % in tumor tissues (11 of 86 cases) and 
zero for normal mucosa (68). So (On the other side), 
it was not appeared a significant association between 
methylation status of FADD gene and risk of OSCC. Re-
garding the FAS gene, the amount of methylation was 
60.46 % for cases (52 of 86) and 39.54% (22 of 68) for 
controls that this difference statistically, was significant 
between groups (P< 0.001). In addition, it was appeared 
a significant association between methylation status of 
FAS gene and increased risk of OSCC (OR=2.622, 95% 
CI; 1.18-5.82, P< 0.018).
-FADD and FAS mRNA levels
Assessment of relative gene expression was done accord-
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A
?
B?
?
?
Fig. 1. Selcted CPG island for MSP amplification, near to transcription start point A: 
FADD-001 ENST00000301838 and B; FAS-003 ENST00000460510.
Genes              Sequences (5’-3’) Annealing temperature (°C) 
FADD  M
FADD    U
FAS     M
FAS       U
F:CCTACAAATAACCCAACTCTCTACG
R: ATTTTTTACGTTTGTTTTTAAACGT
F:TACAAATAACCCAACTCTCTACAAT
R: ATTTTTTATGTTTGTTTTTAAATGT
F:AGTTTTTAGAAAGGGTAGGAGGTC
R:ATTAATTCAACAACTTAACCTACGC
F:AGTTTTTAGAAAGGGTAGGAGGTTG
R:TCCATTAATTCAACAACTTAACCTACA
51
54           
60
62
Table 3. Primer sequences and annealing temperatures.
?
Fig. 2. Methylation analysis of FADD gene: M: amplified product regoconizse by methylated primer (194 bp) U: amplified product 
regoconizse by unmethylated primer (192bp); L: ladder 100 bp: PM and PU (Human HCT116 DKO Methylated and Unmethyla-
tion DNA, D5014-1,2: Zymo Research California, USA).
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?
Fig. 3. Methylation analysis of FAS gen, M: amplified product regoconizse by methylated primer( 160bp), U: amplified product 
regoconizse by unmethylated primer( 165bp), L: ladder  100 bp.
Genes                            Sequences (5’-3’) Annealing  temperature (°C)
FADD
FAS
RNA 18S
F: ACTGTTGCGTTCTCCTTCTCT
R: GCTGGCTCGTCAGCTCAAA
F: GGTGCAAGGGTCACAGTGTT
R:TGAAGGACATGGCTTAGAAGTG
F: GTAACCCGTTGAACCCCATT
R: CCATCCAATCGGTAGTAGCG
60
60
60
Table 4. Real-time primer sequences and annealing temperatures.
Genes Methylation 
status
Cont rol 
(N=68)
Case (N=86) P Value
FADD M
U
0 (-)
68 (100)
11 (12.79)
75 (87.21)
0.001
FAS M
U
22 (32.35)
46 (67.65)
52 (60.46)
34 (39.54)
0.001
Table 5. Promoter methylation frequency of FADD and FAS genes in patients with 
OSCC and healthy controls.
Table 6. Risk of  OSCC based on gene promoter methylation. ?
Unadjusted Adjusted 
Genes OR 95%CI P Value OR 95%Cl P Value 
b
FADD U 
(ref) 
           M 
1.11 0.00 0.999 4.744 0.00 0.998
FAS    U 
(ref) 
           M 
2.96 1.45-6.02 0.003 2.622 1.18-5.82 0.018
ing to dividing CT target gene to CT housekeeping gene 
for FADD and FAS between groups. As shown in table 7, 
the mean of relative expression for FADD was 0.9527±0.57 
in cases (n=25) and 1.9068 ±0.48 in controls (n=19). The 
FAS outcomes were 0.96±0.58 for cases (n=25) and 1.9926 
±0.36   for controls (n=20). The differences of relative gene 
expression between patients and healthy individuals were 
statistically significant for both of them (P< 0.0001).
Genes No. Mean±SD P Value a
FADD Cases
Controls
25
20
0.9527±0.57
1.9068 ±0.48
p<0.0001
FAS Cases
Controls
25
20
0.96±0.58
1.9926 ±0.36
p<0.0001
Table 7. Comparison of relative gene expression for FADD and FAS 
genes between patients with OSCC and healthy controls.
a Mann-witney test. 
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Discussion
Epigenetics is a study of heritable variations that inter-
feres in gene function without modifying the DNA se-
quences (21). It is responsible for the stable maintenance 
of a particular gene expression pattern through the cell 
cycle. The realizing of epigenetic mechanisms, includ-
ing DNA methylation and chromatin remodeling, have 
shown a rapid progress in diagnosis and treatment of 
various diseases (22). These variations may induce gene 
silencing, imprinting and RNA interference that may 
lead to unusual modification as tumorigenesis (23). The 
results of methylation analysis in this study showed sta-
tistically, significant difference in amount of promoter 
methylation status between cases and healthy controls.
In line our results, Li W et al., (2011) shown that the rate 
of FAS promoter methylation in bladder urothelial car-
cinoma samples is higher than normal samples (p<0.01) 
(24). In addition, a vast literatures have been highlighted 
the aberrant promoter methylation of FAS gene in dif-
ferent types of cancers including Lymphomas, CXCA, 
melanoma, Colon, Prostatic and Lung (25-28).
To play a significant role in down regulation of FAS and 
FADD expression in early stage of tumorogenesis. The 
outcomes of the present gene expression analysis ex-
posed a higher ratio of expression for FADD and FAS in 
patients with OSCC than healthy controls.
FAS and FADD are the most important elements of 
the apoptotic pathway with role of removing of harm-
ful, damaged, or unwanted cells (29). Some studies 
have suggested that impairment of FAS gene expres-
sion links with development of various tumors such as; 
stomach, esophagus and liver (30-32). Muraki et al., 
(2000) have reported the increased expression of FAS 
gene in lower stage of SCC, it might operate as a con-
trolling factor to promote apoptosis at the first step of 
disease but, in advanced stage of the disease has been 
detected to be down-regulated (33,34). The expression 
of the FADD has been found to be linked with non-small 
cell lung cancer and poor survival in laryngeal carci-
noma (35,36). Accordance to our study, Lo Mozio et al., 
(2008) reported that there is a significant difference for 
expression of FADD gene between OSCC patients and 
healthy controls (37,38). In summary, this study tried to 
demonstrate the patterns of FAS and FADD genes meth-
ylation and expression profile in OSCC within a South-
eastern Iranian population. The different expression of 
these genes between ill and normal groups is highlight-
ing their significant role in development of OSCC. Ul-
timately. It should be mentioned that mathylation could 
be one of the reasons of gene expression changes. There-
fore, we would like to suggest further studies to identify 
exact molecular process of the disease using advanced 
molecular techniques such as Micro Array  and Meth 
Light in various and larger genetic populations. 
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